Brief: Genmab And Abbvie Provide Clarification On Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (Duobody®-Cd3xcd20) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)
23/07/2026 21:54
BRIEF-Genmab And Abbvie Provide Clarification On Phase 3 Epcore® Dlbcl-1 Trial Evaluating Epcoritamab (Duobody®-Cd3xcd20) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) July 23 (Reuters) - Abbvie Inc ABBV.N:
GENMAB AND ABBVIE PROVIDE CLARIFICATION ON PHASE 3 EPCORE® DLBCL-1 TRIAL EVALUATING EPCORITAMAB (DUOBODY®-CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
GENMAB: CLARIFY OVERALL SURVIVAL (OS) WAS SOLE U.S. PRIMARY ENDPOINT IN PHASE 3 EPCORE(®) DLBCL-1 TRIAL AND WAS NOT MET
Source text: ID:nBw2yw6H8a
Further company coverage: ABBV.N
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96